1. Generics Bulletin
  2. >>Business

Sun Pharma Focuses On Expanding In The Chinese Generic Market

 
• By Akriti Seth

Sun Pharma continues to build its global specialty business with an increasing focus on China and Japan. As it revealed first-quarter results, the company announced a licensing deal with CMS and a new leader for its operations in China.

China_Map
Sun Pharma has linked with local player CMS to target China's generics market • Source: Shutterstock

Sun Pharmaceutical Industries has entered into a collaboration with China Medical System Holdings (CMS) to develop and commercialize seven undisclosed generic products in mainland China. The agreement with the Chinese sales and marketing specialist builds on deals announced in late June this year whereby the Indian firm exclusively licensed to CMS two speciality products, the novel psoriasis treatment Ilumya (tildrakizumab) and Cequa (cyclosporine A) 0.09% eye drops, for marketing in Greater China.

“This collaboration gives us entry into the Chinese generic pharmaceutical market,” commented Sun’s managing director Dilip Shanghvi

More from Deals

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.